Enanta Pharmaceuticals(ENTA)
$8.69-1.98 (-18.56%)
ENTA
Enanta Pharmaceuticals financials statements
$8.69
At close:-1.98 (-18.56%)
Want to see ENTA full AI Analyst Report?
Enanta Pharmaceuticals (ENTA) Ratios
191 Followers
Enanta Pharmaceuticals Ratios
ENTA's free cash flow for Q3 2026 was $-9.98M. For the 2026 fiscal year, ENTA's free cash flow was decreased by $-7.00K and operating cash flow was $-9.97M. See a summary of the company’s cash flow.
| Ratios | Sep 25 | Sep 24 | Sep 23 | Sep 22 | Sep 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.21 | 5.21 | 6.73 | 10.45 | 8.82 |
| Quick Ratio | 4.21 | 5.21 | 6.73 | 10.45 | 8.82 |
| Cash Ratio | 0.67 | 0.65 | 1.36 | 1.47 | 1.58 |
| Solvency Ratio | -0.36 | -0.46 | -0.54 | -2.00 | -1.83 |
| Operating Cash Flow Ratio | -0.40 | -1.37 | -1.64 | -2.84 | -1.94 |
| Short-Term Operating Cash Flow Coverage | -0.63 | -2.29 | -2.94 | -29.33 | -16.65 |
| Net Current Asset Value | $ -11.68M | $ 52.01M | $ 177.25M | $ 252.46M | $ 277.59M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.72 | 0.60 | 0.48 | 0.07 | 0.02 |
| Debt-to-Equity Ratio | 3.11 | 1.75 | 1.03 | 0.08 | 0.02 |
| Debt-to-Capital Ratio | 0.76 | 0.64 | 0.51 | 0.08 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.63 | 0.51 | 0.43 | 0.00 | 0.00 |
| Financial Leverage Ratio | 4.34 | 2.92 | 2.13 | 1.18 | 1.10 |
| Debt Service Coverage Ratio | -1.80 | -2.26 | -3.14 | -41.09 | -18.00 |
| Interest Coverage Ratio | -11.11 | -11.12 | -26.65 | 0.00 | 0.00 |
| Debt to Market Cap | 0.56 | 0.78 | 0.84 | 0.00 | 0.00 |
| Interest Debt Per Share | 9.78 | 11.20 | 10.85 | 1.30 | 0.34 |
| Net Debt to EBITDA | -2.38 | -1.81 | -1.11 | 0.15 | 0.48 |
| Profitability Margins | |||||
| Gross Profit Margin | 92.98% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | -116.14% | -157.98% | -158.89% | -141.82% | -110.82% |
| EBITDA Margin | -108.35% | -154.52% | -155.90% | -138.36% | -107.39% |
| Operating Profit Margin | -130.65% | -179.92% | -173.23% | -143.74% | -112.88% |
| Pretax Profit Margin | -127.90% | -174.15% | -165.39% | -141.82% | -110.82% |
| Net Profit Margin | -125.36% | -171.58% | -168.95% | -141.31% | -81.38% |
| Continuous Operations Profit Margin | -125.36% | -171.58% | -168.95% | -141.31% | -81.38% |
| Net Income Per EBT | 98.01% | 98.52% | 102.15% | 99.65% | 73.43% |
| EBT Per EBIT | 97.89% | 96.79% | 95.47% | 98.66% | 98.18% |
| Return on Assets (ROA) | -29.17% | -30.81% | -28.95% | -31.99% | -17.92% |
| Return on Equity (ROE) | -126.53% | -90.09% | -61.74% | -37.89% | -19.78% |
| Return on Capital Employed (ROCE) | -36.76% | -38.13% | -34.35% | -35.31% | -27.08% |
| Return on Invested Capital (ROIC) | -31.44% | -33.76% | -31.19% | -34.89% | -19.68% |
| Return on Tangible Assets | -29.17% | -30.81% | -28.95% | -31.99% | -17.92% |
| Earnings Yield | -32.06% | -52.94% | -57.13% | -11.39% | -6.89% |
| Efficiency Ratios | |||||
| Receivables Turnover | 9.49 | 1.75 | 2.00 | 1.76 | 1.60 |
| Payables Turnover | 2.35 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.90 | 0.92 | 2.28 | 2.90 | 9.11 |
| Asset Turnover | 0.23 | 0.18 | 0.17 | 0.23 | 0.22 |
| Working Capital Turnover Ratio | 0.33 | 0.22 | 0.25 | 0.31 | 0.28 |
| Cash Conversion Cycle | -116.59 | 208.55 | 182.57 | 207.73 | 228.73 |
| Days of Sales Outstanding | 38.45 | 208.55 | 182.57 | 207.73 | 228.73 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 155.04 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 38.45 | 208.55 | 182.57 | 207.73 | 228.73 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.90 | -3.72 | -4.92 | -4.12 | -3.47 |
| Free Cash Flow Per Share | -1.51 | -4.57 | -5.35 | -4.22 | -3.51 |
| Dividend Paid and CapEx Coverage Ratio | -1.49 | -4.39 | -11.39 | -39.90 | -93.33 |
| Capital Expenditure Coverage Ratio | -1.49 | -4.39 | -11.39 | -39.90 | -93.33 |
| Operating Cash Flow Coverage Ratio | -0.10 | -0.35 | -0.46 | -3.18 | -10.24 |
| Operating Cash Flow to Sales Ratio | -0.30 | -1.16 | -1.30 | -0.98 | -0.72 |
| Free Cash Flow Yield | -12.60% | -44.12% | -47.91% | -8.13% | -6.17% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3.12 | -1.89 | -1.75 | -8.78 | -14.51 |
| Price-to-Sales (P/S) Ratio | 3.91 | 3.24 | 2.96 | 12.40 | 11.80 |
| Price-to-Book (P/B) Ratio | 3.95 | 1.70 | 1.08 | 3.33 | 2.87 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -7.94 | -2.27 | -2.09 | -12.30 | -16.20 |
| Price-to-Operating Cash Flow Ratio | -13.25 | -2.78 | -2.27 | -12.61 | -16.37 |
| Price-to-Earnings Growth (PEG) Ratio | 0.10 | 0.13 | -0.22 | -0.17 | -0.12 |
| Enterprise Value Multiple | -5.99 | -3.90 | -3.01 | -8.82 | -10.51 |
| Enterprise Value | 424.15M | 408.01M | 371.28M | 1.05B | 1.10B |
| EV to EBITDA | -5.99 | -3.90 | -3.01 | -8.82 | -10.51 |
| EV to Sales | 6.49 | 6.03 | 4.69 | 12.20 | 11.29 |
| EV to Free Cash Flow | -13.19 | -4.22 | -3.31 | -12.10 | -15.49 |
| EV to Operating Cash Flow | -22.01 | -5.18 | -3.60 | -12.40 | -15.65 |
| Tangible Book Value Per Share | 3.03 | 6.09 | 10.34 | 15.60 | 19.80 |
| Shareholders’ Equity Per Share | 3.03 | 6.09 | 10.34 | 15.60 | 19.80 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.02 | 0.01 | -0.02 | 0.00 | 0.27 |
| Revenue Per Share | 3.06 | 3.20 | 3.78 | 4.18 | 4.81 |
| Net Income Per Share | -3.84 | -5.48 | -6.38 | -5.91 | -3.92 |
| Tax Burden | 0.98 | 0.99 | 1.02 | 1.00 | 0.73 |
| Interest Burden | 1.10 | 1.10 | 1.04 | 1.00 | 1.00 |
| Research & Development to Revenue | 1.63 | 1.94 | 2.06 | 1.91 | 1.79 |
| SG&A to Revenue | 0.67 | 0.86 | 0.67 | 0.53 | 0.34 |
| Stock-Based Compensation to Revenue | 0.28 | 0.40 | 0.36 | 0.31 | 0.22 |
| Income Quality | 0.24 | 0.68 | 0.77 | 0.70 | 0.89 |
Currency in USD

